InflaRx (IFRX) Non-Current Deferred Tax Liability (2019 - 2026)
InflaRx's (IFRX) quarterly Non-Current Deferred Tax Liability came in at $669358.6 in Q1 2026, up 56.28% year-on-year from $428310.5 in Q1 2025, and down 10.29% quarter-over-quarter from $746120.5 in Q4 2025.
InflaRx (IFRX) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
InflaRx has disclosed Non-Current Deferred Tax Liability across 8 years of filings, most recently posting $669358.6 for Q1 2026.
- Non-Current Deferred Tax Liability for Q1 2026 came in at $669358.6, up 56.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $669358.6 (up 56.28% YoY), and the FY2025 annual result was $746120.5, up 71.97% from the prior year.
- Non-Current Deferred Tax Liability came in at $669358.6 for Q1 2026 at InflaRx, down from $746120.5 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.2 million in Q2 2022 to a low of $428310.5 in Q1 2025.
- The 5-year median for Non-Current Deferred Tax Liability is $802345.6 (2023), against an average of $791667.8.
- Across the five-year window, Non-Current Deferred Tax Liability surged 173.79% in 2022 and slumped 45.92% in 2024, its largest moves.
- InflaRx's Non-Current Deferred Tax Liability stood at $1.0 million in 2022, then slipped by 20.35% to $802345.6 in 2023, then plunged by 45.92% to $433871.1 in 2024, then jumped by 71.97% to $746120.5 in 2025, then dropped by 10.29% to $669358.6 in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $669358.6 (Q1 2026), $746120.5 (Q4 2025), and $818506.9 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 669,358.61 |
| Mar 31, 2026 | 669,358.61 |
| Dec 31, 2025 | 746,120.46 |
| Dec 31, 2025 | 746,120.46 |
| Sep 30, 2025 | 818,506.91 |
| Sep 30, 2025 | 818,506.91 |
| Jun 30, 2025 | 447,388.96 |
| Jun 30, 2025 | 447,388.96 |
| Mar 31, 2025 | 428,310.51 |
| Mar 31, 2025 | 428,310.51 |
| Dec 31, 2024 | 433,871.10 |
| Dec 31, 2024 | 433,871.10 |
| Sep 30, 2024 | 547,932.46 |
| Sep 30, 2024 | 547,932.46 |
| Jun 30, 2024 | 647,419.43 |
| Jun 30, 2024 | 647,419.43 |
| Mar 31, 2024 | 789,848.01 |
| Mar 31, 2024 | 789,848.01 |
| Dec 31, 2023 | 802,345.61 |
| Dec 31, 2023 | 802,345.61 |